[Psychiatric disorders and neural mechanisms underlying energy intake and expenditure: a review].
Anorexia is one of the common symptoms caused by various psychiatric disorders. Increasing evidence indicates that neuroleptics can induce weight gain, obesity, and diabetes mellitus. However, the mechanisms underlying these conditions have not been fully elucidated. In this review, we describe molecular neuroanatomic aspects of current biology of energy homeostasis that would help to address the psychiatric issues noted above, focusing on the central leptin/melanocortin system. An adipocyte-derived hormone, leptin acts on the arcuate hypothalamic nucleus (Arc) to inhibit feeding behavior and simultaneously to promote energy expenditure. Leptin activates Arc neurons producing alpha-melanocyte-stimulating hormone (alpha-MSH) and inhibits those producing agouti-related protein (AgRP). alpha-MSH is an endogenous agonist for the melanocortin-4 receptor (MC4-R) that is expressed exclusively in the central nervous system (CNS), whereas AgRP acts as a MC4-R antagonist. It is also established that MC4-R blockade produces an over-eating/obesity syndrome in rodents and humans. Thus, MC4-R-expressing neurons are downstream targets of leptin. Of interest, MC4-R-positive neurons densely populate in CNS sites critical for energy homeostasis and associated with psychiatric disorders, including the paraventricular hypothalamic nucleus and central amygdaloid nucleus. In addition, Arc alpha-MSH neurons receive serotonergic inputs from raphe neurons. Finally, an AgRP gene polymorphism has been associated with anorexia nervosa. These findings suggest that the central melanocortin system is a target for psychiatry.
Kishi
Toshiro
T
Department of Psychiatry, Shimane Medical University, Izumo 693-8501, Japan.
Horiguchi
Jun
J
D054369:Agouti-Related Protein; D000679:Amygdala / Q000166:cytology; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects; D002149:Energy Intake / Q000187:drug effects / Q000235:genetics*; D004734:Energy Metabolism / Q000187:drug effects / Q000235:genetics*; D001068:Feeding and Eating Disorders / Q000209:etiology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D020647:Lateral Thalamic Nuclei / Q000166:cytology; D020738:Leptin / Q000502:physiology*; D001523:Mental Disorders / Q000150:complications*; D009474:Neurons / Q000378:metabolism / Q000502:physiology; D020641:Polymorphism, Single Nucleotide; D011506:Proteins / Q000235:genetics / Q000502:physiology; D044105:Receptor, Melanocortin, Type 4 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000502:physiology; D054411:Receptors, Leptin; D012701:Serotonin / Q000502:physiology; D000521:alpha-MSH / Q000502:physiology
C515198:AGRP protein, human; D054369:Agouti-Related Protein; D014150:Antipsychotic Agents; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D011506:Proteins; D044105:Receptor, Melanocortin, Type 4; D011956:Receptors, Cell Surface; D054411:Receptors, Leptin; D012701:Serotonin; D000521:alpha-MSH